{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:03:13Z","timestamp":1777356193638,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"9096","license":[{"start":{"date-parts":[[1998,1,1]],"date-time":"1998-01-01T00:00:00Z","timestamp":883612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[1998,1]]},"DOI":"10.1016\/s0140-6736(97)06088-1","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T00:46:25Z","timestamp":1027644385000},"page":"83-87","source":"Crossref","is-referenced-by-count":456,"title":["Randomised, double-blind, placebo-controlled trial of interferon \u03b1-2b with and without ribavirin for chronic hepatitis C"],"prefix":"10.1016","volume":"351","author":[{"given":"Olle","family":"Reichard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Norkrans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aril","family":"Fryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Henrik","family":"Braconier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"S\u00f6nnerborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Weiland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(97)06088-1_bib1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(97)06088-1_bib2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","article-title":"Recombinant interferon alfa therapy for chronic hepatitis C","volume":"321","author":"Di Bisceglie","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(97)06088-1_bib3","first-page":"700","article-title":"Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C","volume":"22","author":"Chemello","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00044011-199509050-00001","article-title":"Effect of recombinant or lymphoblastoid interferon-alfa on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A, non-B hepatitis","volume":"9","author":"Bardelli","year":"1995","journal-title":"Clin Drug Invest"},{"key":"10.1016\/S0140-6736(97)06088-1_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/hep.1840190204","article-title":"High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks","volume":"19","author":"Reichard","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","article-title":"A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis","volume":"332","author":"Poynard","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(97)06088-1_bib7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0168-8278(95)80052-2","article-title":"Interferon alfa-2b for chronic hepatitis C: effect of dose increment and duration of treatment on response rates","volume":"23","author":"Lin","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular mechanisms of action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/S0140-6736(97)06088-1_bib9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(97)06088-1_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","article-title":"A pilot study of ribavirin therapy for chronic hepatitis C","volume":"16","author":"Di Bisceglie","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jmv.1890410203","article-title":"Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C","volume":"41","author":"Reichard","year":"1993","journal-title":"J Med Virol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0016-5085(94)90131-7","article-title":"A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C","volume":"107","author":"Brillanti","year":"1994","journal-title":"Gastroenterology"},{"issue":"suppl 2","key":"10.1016\/S0140-6736(97)06088-1_bib17","first-page":"8","article-title":"The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C","volume":"23","author":"Chemello","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0168-8278(97)80103-1","article-title":"Ribavirin enhances the efficacyt but not the adverse effects of interferon in chronic hepatitis C","volume":"26","author":"Schalm","year":"1997","journal-title":"J Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"key":"10.1016\/S0140-6736(97)06088-1_bib21","unstructured":"MJ Tong LM Blatt JG McHutchison Y Hur RL Co A Conrad Early prediction of response to interferon alfa-2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology (in press)."},{"key":"10.1016\/S0140-6736(97)06088-1_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JCM.35.1.187-192.1997","article-title":"Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method","volume":"35","author":"Hawkins","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1099\/0022-1317-74-6-1093","article-title":"Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay","volume":"74","author":"Stuyver","year":"1993","journal-title":"J Gen Virol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib24","first-page":"914","article-title":"Acute and chronic hepatitis revisited","volume":"ii","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(97)06088-1_bib25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib26","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Pathol"},{"issue":"suppl 12","key":"10.1016\/S0140-6736(97)06088-1_bib27","doi-asserted-by":"crossref","first-page":"109S","DOI":"10.1007\/BF02087885","article-title":"Short-term versus sustained response to interferon therapy","volume":"41","author":"Reichard","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/S0140-6736(97)06088-1_bib28","first-page":"395","article-title":"Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alfa combination therapy: evidence for long-term efficacy and safety","volume":"24","author":"Brillanti","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep.1840220406","article-title":"Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C","volume":"22","author":"Martinot-Peignoux","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/(SICI)1096-9071(199604)48:4<354::AID-JMV9>3.0.CO;2-6","article-title":"Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alfa therapy in chronic hepatitis C patients","volume":"48","author":"Toyoda","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib12","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","article-title":"Ribavirin as therapy for chronic hepatitis C","volume":"123","author":"Di Bisceglie","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(97)06088-1_bib13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(05)80550-1","article-title":"Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon","volume":"19","author":"Camps","year":"1993","journal-title":"J Hepatol"},{"issue":"suppl 2","key":"10.1016\/S0140-6736(97)06088-1_bib16","first-page":"17","article-title":"Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who failed to achieve sustained response to interferon alone: Swedish experience","volume":"23","author":"Schvarcz","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/S0140-6736(97)06088-1_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00365549509032725","article-title":"Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study","volume":"27","author":"Braconier","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/S0140-6736(97)06088-1_bib30","first-page":"1351","article-title":"Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level","volume":"22","author":"Yamada","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/S0140-6736(97)06088-1_bib31","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0140-6736(93)90635-T","article-title":"Significance of serum hepatitis C virus RNA levels in chronic hepatitis C","volume":"341","author":"Lau","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(97)06088-1_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/00365549409011794","article-title":"Serum hepatitis C virus RNA levels in chronic hepatitis C: importance for outcome of interferon alfa-2b treatment","volume":"26","author":"Yun","year":"1994","journal-title":"Scand J Infect Dis"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673697060881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673697060881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T19:14:45Z","timestamp":1580843685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673697060881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,1]]},"references-count":33,"journal-issue":{"issue":"9096","published-print":{"date-parts":[[1998,1]]}},"alternative-id":["S0140673697060881"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(97)06088-1","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[1998,1]]}}}